Emile Nuwaysir, Ensoma CEO
January 5, 2023 04:45 PM ESTUpdated January 9, 06:03 PM
Financing
Deals
Cell/Gene Tx

On in vi­vo cell ther­a­py quest, Take­da-backed En­so­ma buys a CRISPR up­start and bags $85M

Kyle LaHucik

Senior Reporter

Cell ther­a­py biotech En­so­ma made an all-stock ac­qui­si­tion of Dan­ish CRISPR tech­nol­o­gy up­start Twelve Bio, and al­so raised an $85 mil­lion Se­ries B.

The Boston …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

US with­draw­al from WHO could jeop­ar­dize in­for­ma­tion shar­ing

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

Sanofi says no sup­ply in­ter­rup­tions af­ter land­ing FDA warn­ing let­ter for US site

Re­newed mifepri­s­tone fight will be ear­ly test of Trump’s abor­tion stance in his sec­ond term

J&J's Spra­va­to wins ex­pand­ed la­bel for de­pres­sion as sin­gu­lar treat­ment

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times